UC69: Clinical Pharmacist Review (MTM)

The Problem

Polypharmacy (patients on 5+ medications) is increasingly common in elderly and multi-comorbid populations. Polypharmacy increases risk of drug-drug interactions, duplicate therapy, and inappropriate medications. Medicare Part D requires Medication Therapy Management (MTM) programs for eligible beneficiaries (typically those taking 5+ Part D drugs with annual out-of-pocket spending >$4,700). Pharmacists must manually identify MTM-eligible patients, review medication lists for interactions and appropriateness, and generate clinical recommendations. Manual review is time-intensive and reactive. Many eligible patients never receive MTM due to resource constraints.

What the Agent Does

MTM Eligibility Screening: Identifies all Medicare Part D beneficiaries meeting MTM criteria (5+ Part D drugs, $4,700+ annual spend); prioritizes patients by medication complexity and interaction risk.
Interaction & Duplication Analysis: Performs comprehensive drug-drug and drug-disease interaction checking using Lexicomp/Micromedex databases; identifies duplicate therapy (e.g., two NSAIDs prescribed concurrently); generates severity-ranked interaction list.
Deprescribing Recommendations: Identifies medications appropriate for discontinuation per deprescribing guidelines (e.g., statins in very elderly with limited life expectancy, benzodiazepines in fall-risk patients); provides clinical rationale and tapering protocols.
Dose Appropriateness Checking: Evaluates doses against renal/hepatic function, patient age, and clinical guidelines; flags doses that are excessive or suboptimal.
MTM Clinical Summary Generation: Compiles agent findings into MTM clinical summary report ready for pharmacist review; includes interaction severity, deprescribing recommendations, and dose adjustments; prioritizes recommendations by clinical impact.
Pharmacist Handoff & Documentation: Generates suggested MTM documentation template for pharmacist; tracks which recommendations were accepted/rejected; updates medication records if pharmacist approves changes.

Data Requirements

Aspect	Details
Data Sources	Medicare Part D claims data (CMS), active medication list (pharmacy system), diagnosis codes (EHR), lab results (renal function, liver function), prior authorization history, deprescribing guidelines (American Geriatrics Society, CDC). Systems: pharmacy dispensing, EHR, PBM claims system.
Data Classification	PHI (medication list, lab results, claims data), CMS Part D data classification
Data Quality Needs	High , medication list must be current; diagnosis codes must reflect active conditions; lab values must be recent (within 6 months).
Complexity	Moderate-to-High , interaction database queries, renal dosing calculations, guideline interpretation.

Score Breakdown

Criterion	Weight	Score (1-5)	Weighted
Time Recaptured	15%	4	0.60
Error Reduction	10%	3	0.30
Cost Avoidance	10%	4	0.40
Strategic Leverage	5%	3	0.15
Data Availability	15%	3	0.45
Process Clarity	15%	3	0.45
Ease of Implementation	10%	3	0.30
Fallback Available	10%	4	0.40
Audience (Int/Ext)	10%	4	0.40
Composite	100%		3.65

Why It Scores Well

CMS Mandate & Quality Metric: MTM is a CMS requirement for certain beneficiaries; agent ensures compliance and increases reach.
Clinical Evidence Strong: MTM interventions reduce hospitalizations and adverse events; ROI demonstrated in literature.
Scale & Frequency: Applies to millions of Medicare beneficiaries; can be executed monthly for continuous optimization.
Pharmacist Productivity Enabler: Frees pharmacist time from manual chart review to focus on clinical judgment and patient counseling.
Low Regulatory Burden: MTM is established program; agent automates existing workflows with no new regulatory requirements.

Regulatory Alignment

CMS Part D MTM Requirements: Agent screens for eligibility per CMS criteria; generates required documentation; supports compliance audits.
HIPAA: All patient data handled securely; access audited; only authorized users access MTM summaries.
State Pharmacy Practice Acts: Pharmacist retains clinical responsibility; agent provides recommendations only; pharmacist makes final medication decisions.
Joint Commission: MTM programs contribute to patient safety standards.

Sprint Factory Fit

High Fit. Data integration straightforward (pharmacy + PBM systems). Interaction checking via mature APIs (Lexicomp, Micromedex). Deprescribing guidelines can be coded as decision trees. Initial build: 4 weeks for core MTM eligibility + interaction checking. Integration with EHR/pharmacy: 2 weeks. Deployment: Batch job running monthly + interactive pharmacist dashboard.

Comparable Implementations

Mirixa MTM Platform , MTM program baseline.
OutcomesMTM Pharmacist Tools , Clinical pharmacist support platform.
CMS Part D MTM Requirements Documentation , Regulatory framework reference.

Deploy This Use Case with the Sprint Factory

From zero to a governed, production agent in 6 weeks.

Sprint Factory Schedule a Briefing

Related Use Cases

Workflow Pharmacy/Clinical

Pharmacy Prior Authorisation (Provider Side)

Score: 3.9/5.0

Real-Time Pharmacy/Clinical

Opioid Risk Scoring Agent

Score: 3.85/5.0

On-Demand Pharmacy/Clinical

Pill Identification Agent

Score: 3.35/5.0